` SN (Smith & Nephew PLC) vs FTSE All Share Index Comparison - Alpha Spread

SN
vs
FTSE All Share Index

Over the past 12 months, SN has outperformed FTSE All Share Index, delivering a return of -1% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
SN vs FTSE All Share Index

Loading

Performance Gap
SN vs FTSE All Share Index

Loading
SN
FTSE All Share Index
Difference

Performance By Year
SN vs FTSE All Share Index

Loading
SN
FTSE All Share Index
Add Stock

Competitors Performance
Smith & Nephew PLC vs Peers

FTSE All Share Index
SN
ABT
ISRG
BSX
SYK
Add Stock

Smith & Nephew PLC
Glance View

Economic Moat
None
Market Cap
8.5B GBX
Industry
Health Care

Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.

SN Intrinsic Value
1 290.167 GBX
Undervaluation 25%
Intrinsic Value
Price
Back to Top